1. Home
  2. FRD vs STTK Comparison

FRD vs STTK Comparison

Compare FRD & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Friedman Industries Inc.

FRD

Friedman Industries Inc.

HOLD

Current Price

$19.52

Market Cap

139.3M

Sector

Industrials

ML Signal

HOLD

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$3.10

Market Cap

119.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRD
STTK
Founded
1965
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Steel/Iron Ore
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
139.3M
119.0M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
FRD
STTK
Price
$19.52
$3.10
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$4.00
AVG Volume (30 Days)
23.0K
224.7K
Earning Date
11-10-2025
11-06-2025
Dividend Yield
0.82%
N/A
EPS Growth
43.48
N/A
EPS
1.63
N/A
Revenue
$510,450,000.00
$1,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$11.97
N/A
Revenue Growth
8.72
N/A
52 Week Low
$12.24
$0.69
52 Week High
$23.50
$3.12

Technical Indicators

Market Signals
Indicator
FRD
STTK
Relative Strength Index (RSI) 44.85 79.66
Support Level $18.46 $1.93
Resistance Level $19.99 $2.18
Average True Range (ATR) 1.10 0.20
MACD -0.09 0.12
Stochastic Oscillator 24.17 98.42

Price Performance

Historical Comparison
FRD
STTK

About FRD Friedman Industries Inc.

Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: